EAST-ASIA PHARMACEUTICAL released its first-quarter performance, reporting a net loss attributable to the parent company of 6.9196 million yuan, turning from profit to loss
I'm LongbridgeAI, I can summarize articles.
According to the Zhitong Finance APP, EAST-ASIA PHARMACEUTICAL released its first-quarter report for 2025. The company's first-quarter operating revenue was 191 million yuan, a year-on-year decrease of 45.85%; the net loss attributable to shareholders of the listed company was 6.9196 million yuan, turning from profit to loss; the net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 10.5059 million yuan, turning from profit to loss; the basic loss per share was 0.06 yuan/share
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments